Efficacy and safety of a lactiplantibacillus plantarum and bifidobacterium bifidum complex for dry eye disease: a randomized, double-blind, placebo-controlled trial

Dry eye disease (DED) is a prevalent ocular condition associated with systemic inflammation, and the gut–eye axis has emerged as a potential therapeutic target. This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of LB-101, a probiotic complex comprising Lactiplantibacillus plantarum NK151 and Bifidobacterium bifidum NK175, in adults with DED. Eighty participants were randomized to LB-101 or placebo once daily for 8 weeks, of whom 62 participants completed the study and were included in the final efficacy analysis. After 8 weeks, the LB-101 group demonstrated a statistically significant improvement in tear break-up time compared to placebo (mean difference: 1.01 s, 95% CI 0.01–2.01, p = 0.047). Significant improvements were also observed in certain individual symptom-level Ocular Surface Disease Index (OSDI) items. However, total OSDI scores and most other objective ocular surface endpoints did not differ significantly between the groups. Exploratory gut microbiota analysis revealed a significant increase in Carnobacteriaceae and a decrease in the endotoxin-producing bacterial family Oxalobacteraceae in the LB-101 group. No serious adverse events occurred. In conclusion, oral administration of LB-101 for 8 weeks improved tear film stability and certain symptom-level OSDI items, although total OSDI and most objective endpoints remained nonsignificant, with exploratory microbiome findings supporting the therapeutic relevance of the gut–eye axis in DED.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-13
DOI
https://doi.org/10.1038/s41598-026-79278-4
Primary Topic
Ocular Surface and Contact Lens
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and safety of a lactiplantibacillus plantarum and bifidobacterium bifidum complex for dry eye disease: a randomized, double-blind, placebo-controlled trial

Seung-Won Han, Choul Yong Park, Mi‐Young Jung, Yengwoo Son et al.
1 links
Scientific Reports
Ocular Surface and Contact Lens
article

Efficacy and safety of a lactiplantibacillus plantarum and bifidobacterium bifidum complex for dry eye disease: a randomized, double-blind, placebo-controlled trial

Seung-Won Han, Choul Yong Park, Mi‐Young Jung, Yengwoo Son, Dong-Hyun Kim, Seok-Won Jang, Yoon-Jung Shin
article en

Abstract

Dry eye disease (DED) is a prevalent ocular condition associated with systemic inflammation, and the gut–eye axis has emerged as a potential therapeutic target. This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of LB-101, a probiotic complex comprising Lactiplantibacillus plantarum NK151 and Bifidobacterium bifidum NK175, in adults with DED. Eighty participants were randomized to LB-101 or placebo once daily for 8 weeks, of whom 62 participants completed the study and were included in the final efficacy analysis. After 8 weeks, the LB-101 group demonstrated a statistically significant improvement in tear break-up time compared to placebo (mean difference: 1.01 s, 95% CI 0.01–2.01, p = 0.047). Significant improvements were also observed in certain individual symptom-level Ocular Surface Disease Index (OSDI) items. However, total OSDI scores and most other objective ocular surface endpoints did not differ significantly between the groups. Exploratory gut microbiota analysis revealed a significant increase in Carnobacteriaceae and a decrease in the endotoxin-producing bacterial family Oxalobacteraceae in the LB-101 group. No serious adverse events occurred. In conclusion, oral administration of LB-101 for 8 weeks improved tear film stability and certain symptom-level OSDI items, although total OSDI and most objective endpoints remained nonsignificant, with exploratory microbiome findings supporting the therapeutic relevance of the gut–eye axis in DED.

Scientific Reports
Samsung Medical Center (KR), Kyung Hee University (KR), Sungkyunkwan University (KR)
Ministry of Science and ICT, South Korea
Good health and well-being
Ocular Surface and Contact Lens
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon